Livoletide
Hyperphagia
Millendo Therapeutics SASprotein_peptidePhase 2/3Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 40/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Hyperphagia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Oxytocin Eric Hollander | Phase 2 | B |
Sandostatin University of British Columbia | Phase 3 | B |
Ard-101 Aardvark Therapeutics, Inc. | Phase 3 | B |
Setmelanotide Rhythm Pharmaceuticals, Inc. | Phase 2 | CCC |
Genotropin Corporacion Parc Tauli | D |
Same molecule, other indications
Livoletide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →